DDInter923 DDInter704
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Zinc sulfate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Etonogestrel {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) FKBP1A
FKBP1A {u} (Gene) is bound by {v} (Compound) Everolimus
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Poliovirus type 1 antigen (formaldehyde inactivated)
Poliovirus type 1 antigen (formaldehyde inactivated) {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Infliximab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Everolimus (Compound)
Infliximab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Infliximab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Everolimus (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Infliximab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) binds FKBP1A (Gene) and FKBP1A (Gene) is bound by Everolimus (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)